Treatment of Recalcitrant Cyclitic Neovascular Pupillary Membranes

J Glaucoma. 2017 Apr;26(4):e160-e162. doi: 10.1097/IJG.0000000000000543.


Purpose: To describe a new approach for the treatment of cyclitic vascularized pupillary membranes.

Patients and methods: A retrospective interventional case series describing 3 patients undergoing a novel interventional treatment at a single institutional center.

Results: This technique allows successful completion of laser membranectomy to create a pupillary aperture. This aperture resulted in improved vision and an enhanced ability to examine for and treat ischemic retinal disease.

Conclusions: This technique describes a new use for bevacizumab that enables the surgeon to treat recalcitrant and recurrent cyclitic vascularized pupillary membranes.

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use*
  • Anterior Eye Segment / blood supply*
  • Bevacizumab / therapeutic use*
  • Combined Modality Therapy
  • Eye Abnormalities / drug therapy
  • Eye Abnormalities / surgery
  • Eye Abnormalities / therapy*
  • Female
  • Humans
  • Intravitreal Injections
  • Laser Coagulation*
  • Lasers, Solid-State / therapeutic use*
  • Male
  • Middle Aged
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / surgery
  • Neovascularization, Pathologic / therapy*
  • Retrospective Studies
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Visual Acuity


  • Angiogenesis Inhibitors
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab

Supplementary concepts

  • Pupillary Membrane, Persistence Of